Drug treatments for polycystic ovary syndrome

Area of Science:

• Endocrinology
• Reproductive Medicine
• Metabolic Disorders

Background:

• Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting 5-10% of women of reproductive age.
• Diagnosis can be challenging due to the subtle and diverse nature of symptoms, including hirsutism, infertility, and menstrual irregularities.
• Insulin resistance is a key biochemical abnormality often associated with PCOS.

Purpose of the Study:

• To review the diagnostic challenges and varied manifestations of Polycystic Ovary Syndrome (PCOS).
• To outline current treatment strategies for PCOS, emphasizing individualized goals and consideration of comorbidities.
• To highlight the role of insulin-sensitizing agents and other pharmacotherapies in managing PCOS symptoms.

Main Methods:

• Review of existing literature on Polycystic Ovary Syndrome diagnosis and treatment.
• Analysis of the efficacy of various therapeutic agents, including insulin-sensitizing medications.
• Consideration of treatment guidelines and contraindications, particularly regarding pregnancy.

Main Results:

• Insulin-sensitizing agents demonstrate significant benefits for insulin resistance, menstrual irregularities, anovulation, hirsutism, and obesity in PCOS patients.
• Metformin is supported by extensive data for PCOS management, while rosiglitazone and pioglitazone also show efficacy.
• Combination therapy with metformin and clomiphene is a first-line approach for ovulation induction.

Conclusions:

• Treatment for PCOS requires a personalized approach targeting specific symptoms and patient objectives.
• Lifestyle modifications are crucial adjuncts to medical therapy for optimal PCOS management.
• Insulin-sensitizing agents, oral contraceptives, spironolactone, and topical eflornithine are valuable in managing hirsutism and other PCOS manifestations.